Oppenheimer Reiterates Outperform on Zimmer Biomet Holdings, Maintains $157 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Steven Lichtman has reiterated an 'Outperform' rating on Zimmer Biomet Holdings (NYSE:ZBH) and maintained a price target of $157.
August 04, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer's reiteration of an 'Outperform' rating and a maintained price target of $157 could positively influence Zimmer Biomet Holdings' stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, Oppenheimer's reiteration of an 'Outperform' rating and a maintained price target of $157 for Zimmer Biomet Holdings could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100